Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

The Patient Experience, Clinical Research and the Promise of Precision Medicine, Upcoming Webinar Hosted by Xtalks


Xtalks Life Science Webinars

This informative webinar will provide insight into the current state of diabetic kidney disease prevalence and recent data on a widespread lack of compliance with accepted clinical management guidelines.

Diabetes is the most common cause of chronic kidney disease (CKD), potentially leading to renal failure and the need for dialysis or transplantation. This informative webinar will provide insight into the current state of diabetic kidney disease prevalence and recent data on a widespread lack of compliance with accepted clinical management guidelines. The voice of the patient will be explored with current research exploring attitudes and challenges facing clinical care for patients with diabetes and renal impairment and their caregivers as well as concerns they have towards participating in clinical research trials. In addition, state-of-the-art approaches using tools of precision medicine to better understand the causes of renal disease in people with diabetes will be discussed.

Join Barry Goldstein, MD, PhD, FACE, Vice President & Therapeutic Area Head, Cardiovascular, Metabolic, Endocrine & Renal, Covance, Mala Puri, MD, Senior Medical Director, CVMER Project Physician, Kelly L. Close, Founder, The diaTribe Foundation; President, Close Concerns and Kumar Sharma, MD, Hillis Endowed Distinguished Chair in Medicine; Director, Center for Renal Precision Medicine; Chief, Division of Nephrology in a live webinar on Wednesday, July 29, 2020 at 11am EDT (4pm BST/UK).

For more information or to register for this event, visit Diabetes and Chronic Kidney Disease (CKD): The Patient Experience, Clinical Research and the Promise of Precision Medicine.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

ThermBot Gets the Green Light to Produce 250,000 Devices After a 5-Minute Phone Call With The FDA


ThermBot

This is incredible news. The go-ahead was given by an FDA Emergency Hotline Senior Agent after just a 5-minute phone call. Truly amazing as the approval process can typically take at least 15 months.

GTTFP Holdings, an Inc 500 #1 Awardee, is proud to announce a product launch that brings the health thermometer into the digital age. ThermBot is the smaller, instant, smarter temperature reader about to make the bulkier models found in your medicine cabinet obsolete.

Thanks to a 5-minute phone call with an FDA Emergency Hotline Senior Agent, ThermBot is mass-producing 250,000 units to bring these devices to the market nationwide. This pocket-sized device is no bigger than a credit card and compact enough to fit in your wallet, purse, pocket, diaper bag, or on a keychain.

ThermBot is “the” fast and effective way to take someone’s temperature in under one second with 100% clinical accuracy. Its contactless operation makes the process healthy and sanitary while its durability withstands repeated use and demanding environments.

The new norm tech accessory is ideal to anyone who needs a handy thermometer. Imagine a parent getting a quick and accurate reading from her child who can’t stay still or is sleeping.

For travelers, it creates little to no baggage to take on road trips or flights. Let’s not forget about those who need to take extra health and safety precautions within their industries. Thermbot operates easily and effectively to ensure they’re work-ready.

A spokesperson for GTTFP Holdings today confirmed that ThermBot has been given the green light by the FDA to mass-produce 250,000 units for immediate resale nationwide.

The spokesperson added, “This is incredible news. The go-ahead was given by an FDA Emergency Hotline Senior Agent after just a 5-minute phone call. Truly amazing as the approval process can typically take at least 15 months.”

Other smart features include an embedded BLE chip that works with existing wellness tracking apps, smart assistants and protocols like IFTTT (If This Then That) platform. Unlike a traditional electronic thermometer that relies on battery power, this smart device draws power directly from your smartphone, power bank, or tablet with a retractable type C connector. ThermBot’s elegant slider button makes it super easy to slide out the Type C connector on-demand and retract it when you’re done.

The most noticeable part of its sleek design is the easy-to-read screen. It also toggles between Fahrenheit and Celsius measurements seamlessly for international use. ThermBot retails for $149.

“We’d like to extend our thanks to the Agent in question and his (FDA crisis) team who worked tirelessly to make this insane (practically unheard of) turnaround for ThermBot’s approval a reality, especially in these unprecedented times,” the spokesperson added.

For more information, contact amber@teamchicexecs.com or view the press kit here.

Share article on social media or email:

Cecelia Health Provides Critical Telehealth Support to Joslin Diabetes Center at SUNY Upstate Medical University, Syracuse


Telehealth Diabetes Care

Telehealth Diabetes Care

Our experience supporting the Joslin Diabetes team and their patients during COVID-19 has highlighted the importance of the diabetes and mental health telemedicine clinic we’ll be launching this month.

In partnership with the Helmsley Charitable Trust, Cecelia Health is providing essential clinical support to people of all ages living with Type 1 and Type 2 diabetes around the country to help them overcome challenges resulting from the COVID-19 pandemic.

Since April, Cecelia Health’s team of Certified Diabetes Care and Education Specialists (CDCES) has been working with the Joslin Diabetes Center at SUNY Upstate Medical University, Syracuse and over 50 other university and hospital clinics who are receiving funding from the Helmsley Charitable Trust. They are assisting both patients and clinicians with providing a spectrum of support in managing their insulin-dependent diabetes to ease the daily burden and help improve outcomes. Cecelia Health’s telehealth model has been a critical element for providing diabetes patients with access to care at time when COVID-19 has prevented them from coming into the clinics to meet with endocrinologists and other clinical staff.

The care Cecelia Health CDCESs are providing includes:


  • Remote initiation, education, and troubleshooting continuous glucose monitors (CGM), blood glucose meters (BGM), insulin pumps and smart pen technologies combined with diabetes education to help patients more successfully manage their diabetes condition
  • Helping patients prepare for scheduled telemedicine visits by teaching them how to upload their CGM and insulin data
  • Educating them on interpreting data from their devices to highlight patterns and trends, thus streamlining and increasing the quality of their visits with the Joslin Diabetes endocrinology team

“Pre-COVID, our clinic was overcrowded, with the waiting room often completely full and providers many times working out of only one exam room.” said Dr. Ruth Weinstock, Founder and Medical Director of the Joslin Diabetes Center at SUNY Upstate Medical University, Syracuse.” Because of this, even as we re-open, telemedicine will have to continue if we are to be safe. We anticipate needing to see almost all our diabetes patients remotely until there is a vaccination.”

Accordingly, Cecelia Health CDCESs have also been working with patients on vital components of a comprehensive diabetes management plan to increase safety such as the use of glucagon, ketone meters, sick day rules, and back-up injection plans.

As the results of this partnership indicate, clinical telehealth support is an important and necessary component of an effective patient care management strategy during COVID-19 and beyond. The diabetes population is very large and growing rapidly and expensive to treat, there are not enough endocrinologists in the U.S. to support them, particularly in rural states and portions of states.

“Our experience supporting the Joslin Diabetes team and their patients during COVID-19 has highlighted the importance of the diabetes and mental health telemedicine clinic we’ll be launching this month. It will enable educating and empowering our patients to successfully manage their condition using diabetes technology, remotely monitoring them, and providing the right interventions to the right patient at the right time. This will increase access to care regardless of geography, optimize health outcomes at the lowest possible cost, and provide a great patient experience.” said Cecelia Health CEO and Founder, David Weingard.

About Cecelia Health

Cecelia Health’s mission is to transform and improve the lives of people living with chronic conditions worldwide. Cecelia Health has a proven track record of driving improved clinical outcomes and return on investment for customers. The Cecelia Health clinical team is comprised of nurses, dietitians, exercise physiologists, pharmacists, and social workers who are passionate about empowering people with chronic conditions to live rich, healthy and fulfilling lives. Cecelia Health partners with ACOs seeking to improve quality measures, and pharmaceutical and medical device companies seeking to improve adherence. Cecelia Health has also engaged in numerous joint initiatives with the JDRF, American Diabetes Association, the Diabetes Research Institute, the Association of Diabetes Care & Education Specialists, and The Helmsley Charitable Trust.

About Upstate Medical University

SUNY Upstate Medical University in Syracuse, NY, is the only academic medical center in Central New York. It is also the region’s largest employer with 9,460 employees. Affiliated with the State University of New York, Upstate’s mission is to improve the health of the community through education, biomedical research and health care. Upstate Medical University’s educational mission is anchored by its four colleges—Medicine, Nursing, Health Professions and Graduate Studies (biomedical sciences). The Upstate University Health System serves 1.8 million people, often the most seriously ill and injured, and includes Upstate University Hospital; Upstate University Hospital at Community Campus; Upstate Golisano Children’s Hospital, and numerous satellite sites.

Share article on social media or email:

Proscia Achieves Key Regulatory Milestone With Medical Device Single Audit Program (MDSAP) Certification


News Image

Proscia®, a leading provider of AI-enabled digital pathology solutions, has received Medical Device Single Audit Program (MDSAP) certification, a rigorous validation of the company’s practices for delivering high quality medical device software. This certification accelerates the company’s expansion into the diagnostic pathology market to help laboratories worldwide keep pace with the rising cancer burden and improve patient outcomes.

MDSAP was established to enable medical device manufacturers to be audited once for compliance with ISO 13485 and the standards of five different markets: United States, Australia, Brazil, Canada, and Japan. In successfully completing the MDSAP audit, Proscia has demonstrated that its quality management system satisfies strict requirements related to the design, development, production, deployment, and sale of its solutions.

“At Proscia, our commitment to quality underlies all that we do,” said Natalia Remmel, Director of Quality and Regulatory Affairs. “The MDSAP certification reflects our focus on building safe and effective solutions to help laboratories scale their digital pathology implementations as they look to deliver faster, more accurate diagnoses.”

The current standard of care for diagnosing cancer relies on the pathologist’s interpretation of patterns in tissue as viewed under a microscope. Proscia is working to transform this 150-year-old manual and subjective practice to address the growing demand for diagnostic services, as pathologists have faced a 42% increase in diagnostic workload over the last decade, and improve patient outcomes. With its Concentriq® Dx digital pathology solution and suite of AI modules, the company is accelerating workflows while driving confidence and quality gains.

Concentriq Dx enables pathologists to securely read and share cases from any location while automating time-consuming, error-prone tasks. The software can be rapidly deployed on existing IT infrastructure and works with leading scanners and laboratory information systems (LIS), offering seamless integrations with Philips, Leica, 3DHISTECH, and Hamamatsu among other solutions.

CE-marked for use in primary diagnosis in Europe, Concentriq Dx is also available for remote use in clinical practice in the United States during the COVID-19 public health emergency. This comes in response to the FDA’s recent guidance aimed at expanding the availability of digital pathology devices.

“From driving meaningful improvements in accuracy and efficiency to enabling remote case review during the public health emergency, Concentriq Dx is helping laboratories to transform their pathology operations at a time when change is more critical than ever before,” said David West, CEO of Proscia. “With our relentless dedication to quality, we are accelerating our expansion into the global diagnostic pathology market to continue advancing the standard of care.”

About Proscia

Proscia is a software company that is changing the way the world practices pathology to transform cancer research and diagnosis. With the company’s Concentriq digital pathology platform and pipeline of AI-powered applications, laboratories are leveraging new kinds of data to accelerate discoveries and improve patient outcomes. Proscia’s team of technologists, scientists, and pathologists is bringing a fresh approach to an outdated industry, helping the world to keep pace with the increasing demand for pathology services and fulfill the promise of precision care. For more information, visit proscia.com.

Share article on social media or email:

Clean the World Endorses American Hotel & Lodging Association’s Safe Stay Initiative


Clean the World Endorses American Hotel & Lodging Association’s Safe Stay Initiative

“The Safe Stay initiative is a comprehensive collection of resources, best practices, and protocols developed by leaders from various aspects of the hotel industry. This is a big win for hotels and takes the guesswork out of how to properly re-open and what expectations to provide to guests.”

Clean the World, a global leader in water, sanitation, hygiene, and sustainability, is endorsing the American Hotel & Lodging Association’s new Safe Stay initiative. The Safe Stay initiative will seek to change hotel industry norms, behaviors, and standards to ensure both hotel guests and employees are confident in the cleanliness and safety of hotels as travel resumes. It includes checklists for enhanced cleaning practices workplace protocols and employee training to meet the new health and safety challenges and more.

“The Safe Stay initiative is a comprehensive collection of resources, best practices, and protocols developed by leaders from various aspects of the hotel industry. This is a big win for hotels and takes the guesswork out of how to properly re-open and what expectations to provide to guests,” says Shawn Seipler, Founder, and CEO, Clean the World.

AHLA’s initiative is focused on enhanced hotel cleaning practices, social interactions, and workplace protocols to meet the new health and safety challenges and expectations presented by COVID-19. The guidelines were created by an Advisory Council comprised of leaders from all segments of the hotel industry in accordance with CDC best practices. Safe Stay is endorsed by all major U.S. hotel brands, associations in all 50 states, and Canada and is quickly becoming the industry’s go-to guidelines as hotels look to re-open.

“Every hotel guest and employee should know that their health and safety are our top priority,” said Chip Rogers, president, and CEO of AHLA. “Safe Stay represents a new level of focus for an industry already built on cleanliness. Hotels have always had rigorous standards for cleaning and safety. With Safe Stay, we are enhancing these standards to help create peace of mind. As travel resumes, hotels are ready to safely welcome back the traveling public.”

For more information, please visit: https://www.ahla.com/safestay

About Clean the World

Clean the World is a social enterprise dedicated to WASH (water, sanitization, and hygiene) and sustainability. It operates soap recycling centers and offices in Orlando, Montreal, Las Vegas, Hong Kong, Netherlands, Washington DC, and Punta Cana and leads a “Global Hygiene Revolution” to distribute recycled soap and hygiene products from more than 8,000 hotel, resort, and cruise partners. Clean the World’s foundation provides WASH (water, sanitization, and hygiene) programming to benefit global communities with high pre-adolescent death rates due to acute respiratory infection (pneumonia) and diarrheal diseases (cholera) – which are two of the top killers of children under the age of five. Since 2009, the foundation has served over 10 million individuals and distributed 56 million bars of soap and 5 million hygiene kits in 127 countries. For more information on how you can participate in Clean the World’s world-renowned recycling program, please visit https://cleantheworld.org/get-involved/hotel-recycling-program/

About AHLA

The American Hotel & Lodging Association (AHLA) is the sole national association representing all segments of the U.S. lodging industry and contributes nearly $660 billion to U.S. GDP. Headquartered in Washington, D.C., AHLA focuses on strategic advocacy, communications support, and workforce development programs to move the industry forward. Every day, America’s hotels make dreams come true, not just for our guests, but also for the 8.3 million people whose jobs we support—more than 1 in every 25 American jobs. Learn more at http://www.ahla.com.

MEDIA CONTACTS:

Sandie Beauchamp

Clean the World

info@cleantheworld.org

407-574-8353

Maura Morton

AHLA

mmorton@ahla.com

202-381-8644

Share article on social media or email:

Palette Life Sciences Continues Global Expansion of Deflux Availability with New Saudi Arabian Distribution Partner, Gulf Horizon Co. Ltd. (GHIM)


News Image

This distribution partnership and registration within Saudi Arabia allows Palette to establish a beachhead within the Middle East, and is an excellent starting point to ensure long-term access to our innovative products for customers and patients in the region” James Leech, Palette Life Sciences

Palette Life Sciences, a fully integrated global life sciences company dedicated to improving patient outcomes, today announced its latest distribution agreement with Gulf Horizon Co. Ltd. (GHIM). GHIM will distribute Palette’s product, Deflux, in Saudi Arabia. GHIM is a medical equipment company that provides hospitals with innovative medical devices for minimally invasive surgery in the Kingdom of Saudi Arabia (KSA). This new distribution agreement with GHIM further extends Palette’s global expansion efforts, and marks the first time Deflux has been directly registered within the KSA.

“This distribution partnership and registration within Saudi Arabia allows Palette to establish a beachhead within the Middle East, and is an excellent starting point to ensure long-term access to our innovative products for customers and patients within the region,” said James Leech, Head of Corporate Development, Palette Life Sciences. “GHIM has vast experience and deep physician relationships within the KSA. We are confident that GHIM will be an excellent partner to aid in our delivery of high quality solutions to physicians and patients. Palette Life Sciences is dedicated to supporting physicians globally in their pursuit of improved patient outcomes. Palette and its network of partners are making several significant investments within local markets to improve physician access to Palette resources, including renewed product training and support.“

For more information or to place an order within a GHIM territory, please contact a GHIM representative at jamil@ghim-sa.com.

About Deflux

Deflux is a minimally invasive, outpatient treatment that has been proven safe and effective in children with vesicoureteral reflux (VUR). VUR is a serious paediatric urinary condition in which urine refluxes from the bladder through one or both ureters toward the kidneys, due to an abnormality at the junction of the ureter and the bladder. Deflux is an injectable gel bulking agent made from two tissue-friendly polysaccharides; Non-Animal Stabilised Hyaluronic Acid (NASHA®) and dextranomer (Dx) microspheres. The product is administered via injection around the ureteral opening to prevent urine reflux. Deflux is indicated for children with all VUR grades and is the recommended first-line treatment for VUR.1 Separate study results show Deflux is an efficacious long-term (15 – 25 years) treatment option for VUR grade IV2 with up to 93% success rates after a one time injection and no post-injection febrile UTIs (19 month results).3 Deflux is the only minimally invasive VUR treatment approved globally across Australia, Canada, Europe, Latin American, Japan, New Zealand and the United States.

About Palette Life Sciences AB

Palette Life Sciences is a fully integrated life sciences company. Palette’s products improve patient outcomes in urology and urogynecology disorders, colorectal conditions, radiotherapy, and interventional oncology procedures. The company’s portfolio of available products includes Deflux®, Solesta® and Barrigel®. Palette Life Sciences moves rapidly to leverage novel applications of existing technologies to create breakthrough medical solutions. This focus enables the company to serve those often overlooked by traditional medical companies and improve patient quality of life. Led by experienced healthcare executives, Palette Life Sciences is headquartered in Stockholm, Sweden, with offices in Santa Barbara, California, and Dallas, Texas. Learn more at http://www.palettelifesciences.com.

References:

1. Elder JS, Shah MB, Batiste LR, Eaddy M. Part 3: Endoscopic injection versus antibiotic prophylaxis in the reduction of urinary tract infection in patients with vesicoureteral reflux. Curr Med Res Opin. 2007;23(4):S15-20.

2. Stenbäck A, Olafsdottir T, Sköldenberg E, Barker G, Läckgren G. Non-animal hyaluronic acid/dextranomer gel (Deflux®) endoscopic treatment in grade IV VUR results after 15-25 years: durable and effective. J Pediatr Urol. 2020.

3. Kalisvaart JF, Scherz HC, Cuda S, Kaye JD, Kirsch AJ. Intermediate to long-term follow-up indicates low risk of recurrence after Double HIT endoscopic treatment for primary vesicoureteral reflux. J Pediatr Urol. 2012;9(4)359-365.

Q-Med AB is the current legal manufacturer and holds the CE Mark.

Deflux®, GHIM®, NASHA®, and Palette Life Sciences™ are registered trademarks.

All rights reserved. APM209A

Share article on social media or email:

modern clinical technology helps scientists to accelerate the development of new therapies and vaccines


The durability, near real time performance and quality of data collection, processing and analysis are instrumental in our daily operations and it is enormously important in the COVID-19 studies

EDETEK, the premier provider of digital clinical trial computer systems, today announced that the company’s cloud-based eClinical and clinical informatics platforms CONFORM™ are supporting multiple clinicals sponsors in research and development of emergent COVID-19 treatments and vaccines.

Jian Chen, EDETEK’s President and CEO, “Our customers use CONFORM ™ in Phase I, II and III COVID-19 clinical trials. In some trials our Platform is used entirely as an end to end clinical system. Customers also implemented selective CONFORM™ components to add efficiency to the existing development workflows. It is exciting to see how rapidly our team and the system can fit into the emergent research and development of the COVID-19 therapies and vaccines. We have invested years in development of the state of the art comprehensive and highly configurable clinical system and I am thrilled to see how it is helping scientists battle the global pandemic”.

The CONFORM™ eClinical suite of study conduct applications is utilized for patient randomization, clinical supply, trial and document management, drug safety monitoring and electronic data capture. CONFORM™ Informatics platform enables rapid ingestion of clinical structured and unstructured data from a variety of clinical data providers, data aggregation, validation, transformation, review and reporting in one system that quickly integrates with information consumers – processes and systems of study sponsors and sites. In the case of COVID-19, CONFORM™ studies were configured, tested, and deployed in a matter of days to meet the highly challenging timelines of clinical development teams.

CONFORM™ was architected to support modern clinical trials that concurrently use variety of systems to collect information. EDC, laboratory systems, instruments, IoT patient wearable devices, imaging, ePRO smart phones, EHR applications represent a typical set of digital sources in a trial. COVID-19 trials employ many of these data providers to study different safety and efficacy indicators in record time.

“Using the capabilities of our Information Hub and Clinical Data Lake to quickly connect and aggregate the data were keys in these implementations. Another main differentiator of CONFORM™ is the event driven model. CONFORM™ is fully event driven and it processes any business and scientific events as well as data loads in real time according to sponsors’ workflow and study configuration. The durability, near real time performance and quality of data collection, processing and analysis are instrumental in our daily operations and it is enormously important in the COVID-19 studies where we receive tens of thousands of data transmissions every day and run complete study data processing and reporting tasks several times a day. The era of a slow-going typical EDC study with a nightly processing batch is gone. COVID-19 has shown us that the traditional model is no longer working”, states Peter Smilansky, Senior Vice President of Product Development and Strategy of EDETEK.

CONFORM™ GxP–compliant technology platform is natively designed for scalable cloud computing. It runs on Amazon Web Services supporting COVID-19 and hundreds of other clinical trials on three continents.

ABOUT EDETEK

EDETEK, Inc. is an innovative clinical solutions company that provides high-quality technology and services to pharmaceutical, biotechnology, and medical device companies. We utilize our clinical platform, CONFORM™, to fulfill our clients’ data engineering, computational and scientific analytics needs. Visit our website at http://www.edetek.com.

Share article on social media or email:

Schlesinger Groups Brands Its Clinical Division as Schlesinger Clinical Research


News Image

Rob Ramirez, EVP Strategic Development

This offering streamlines the research process by bringing site selection, subject enrollment, and study execution expertise under one partner

Schlesinger Clinical Research addresses an unmet need in the market by encompassing all data collection aspects necessary for clinical research under one roof. The company boasts thirty proprietary sites and expert team with principal investigation experience, as well as CITI-certification in Good Clinical Practice and Human Subjects Protection to ensure adherence to study protocols.

Schlesinger Clinical Research offers a single point of contact to oversee the recruitment and consistent application of clinical study research protocols nationwide. The company specializes in Rx-to-OTC and Non-Rx product research that often involves IRB approval and FDA submissions. Schlesinger Clinical Research has worked with many of the world’s largest universities, CROs, CPG, pharma, and insight companies.

As an approved government vendor and fully FDA CFR Part-11 compliant, the company is currently supporting electronic nicotine delivery system (ENDS) manufacturers who are seeking a partner to streamline their clinical testing to meet the September 9th submission deadline for the FDA Premarket Tobacco-Product Applications (PMTA).

The addition of Schlesinger Clinical Research adds high quality regulated research to Schlesinger Group’s portfolio of capabilities, and underscore its position as a highly comprehensive data collection and research services provider.

Commenting on the news, Rob Ramirez, EVP, Strategic Development at Schlesinger Group, said, “This offering streamlines the research process by bringing site selection, subject enrollment, and study execution expertise under one partner for better outcomes”

Share article on social media or email:

3 New Ways Shady Grove Fertility (SGF) is Saving Patients Money


To ease the cost of fertility treatment, Shady Grove Fertility (SGF) has developed three new financial incentives.

To help make cost less of a barrier to seeking care, SGF has developed three new financial options for fertility treatment.

To ease the cost of treatment during these uncertain times, Shady Grove Fertility (SGF) is proud to announce the launch of three new money-saving programs. While many patients have some form of insurance coverage for treatment or live in an area that has coverage provided by a state mandate, SGF recognizes there are some without any insurance coverage or benefits.

To help make cost less of a barrier to seeking care, SGF has developed three new financial options for fertility treatment.

Patients Paying with Cash Receive a 3 Percent Discount

For a limited time only, patients enrolled in SGF’s Shared Risk 100% Refund Program* or Multi-Cycle Discount Program who pay via certified funds or wire transfer will receive a 3 percent discount on fertility treatment.

*Shared Risk 100% Refund Program: discounts do not apply to fees related to an Egg Donor, or Shared Risk riders.

A Deferred First Month Payment Means Patients Can Start Now and Pay Later with $0 Down

Fertility Finance specializes in providing patient financing services for all fertility treatment options. With its easy loan process and competitive rates, Fertility Finance ensures that the financial aspects of treatment are not an obstacle to achieving the dream of parenthood.

For a limited time, SGF has partnered with Fertility Finance to offer flexible first month payment options on all loans funded during July of 2020.

The first loan payment is generally due in the month following that in which loans are finalized. To reduce the economic burden during these trying times, Fertility Finance is providing SGF patients with the following flexible first monthly loan payment option:

1.    For all loans funded during the month of July 2020, borrowers can request that their first monthly loan payment be in EITHER August or September 2020.

To receive this special offer, patients will need to request the desired payment option at the time their loan is finalized.

One patient shared her experience and gratitude working with Fertility Finance to be covered for IVF treatment.

“Two years ago, I was desperately trying to come to terms with the fact that in order to have children, I would need to undergo IVF. I didn’t have money to pay for IVF and I had tried so many other finance companies without success. I filled out a form on your website on a Friday night, thinking I would once again be disappointed. Instead, that night changed my life. I can never fully express my gratitude to Fertility Finance for making my dream of motherhood come true. You are responsible for giving me the most precious gift I will ever receive and I truly thank you from the bottom of my heart.” —Andrea

Click here or call 888-497-8414 to learn more about Fertility Finance.

SGF’s Flexible Payment Program Lets Patients Pay Over Time

For a limited time only, patients now have the option to pay for services over the course of 3 months, as opposed to paying in advance of treatment. This program provides more flexibility and added convenience, with a 60-20-20 payment model. Patients will pay 60 percent their first month, followed by 20 percent the second month, and the remaining 20 percent the third month.

Patients enrolled in SGF’s Multi-Cycle Discount Program or Assure Fertility Financial Program for egg freezing are eligible for this flexible payment program.

More Ways SGF Helps Patients Afford Fertility Treatment

In addition to these new affordable options, SGF offers innovative financial programs, including a 100% refund guarantee program. SGF was the first practice to create an IVF program with a refund guarantee, known as the Shared Risk 100% Refund Program. This exclusive program provides patients with the opportunity to pay a fixed amount for up to six fresh IVF or donor egg cycles and any subsequent frozen embryo transfers (FETs). In the event the patient does not take home a baby, SGF provides a full refund. Eighty-two percent of participants take home a baby.

Other popular programs that make treatment at SGF more affordable include a Shared Help Discount Program, an income-based program that offers a discount on most treatments and procedures, a Military Discount Program, which offers active U.S. military and reservists a discount off qualifying self-pay rates, and a Shared Donor Egg Program, which reduces the cost of donor egg treatment when sharing donated eggs with other patients—an approach that does not lower the chances of conception but significantly lowers the cost.

To learn more or to schedule a virtual consultation with an SGF physician, call 1-888-761-1967.

About Shady Grove Fertility (SGF)

SGF is a leading fertility and IVF center of excellence with more than 85,000 babies born and counting. With 38 locations throughout FL, GA, MD, NY, PA, VA, D.C., and Santiago, Chile, we offer patients virtual physician consults, individualized care, accept most insurance plans, and make treatment affordable through innovative financial options, including treatment guarantees. More physicians refer their patients to SGF than any other center. Call 1-888-761-1967 or visit ShadyGroveFertility.com.

Share article on social media or email:

Established and trusted provider of objective clinical data to physicians and hospitals announces formation of The Hospital Turnaround Company to save troubled hospitals


With its solution suite, Verras helps all parties in the acute health care continuum from payers to providers to leverage their assets and focus on growth

Physicians generate all resources utilized in a hospital. Using our detailed Clinical Acuity Analytics™, we partner with the hospital’s physicians to create the solution quickly by using clinical best practice pathways to lower cost while improving quality.

Dr. Dennis J. Patterson, Founder and Chairman of Verras, 3-decade old healthcare informatics firm, is pleased to announce the formation of its subsidiary, The Hospital Turnaround Company (HTC). HTC will save hospitals in jeopardy of closing its doors on the community they serve. By rejecting a slash and burn approach, it will use an emphasis on quality and cost (value) engaging the medical staff using its patented technology to measure the hospital’s overall and each physician’s outcome of care. “Physicians generate all resources utilized in a hospital,” said Dr. Patterson. “Using our detailed Clinical Acuity Analytics™, we partner with the hospital’s physicians to create the solution quickly by using clinical best practice pathways to lower cost while improving quality. The American College of Healthcare Trustees has endorsed our unique approach.”

Verras was founded in 1982 with a plan to provide transparent data analytics to the healthcare industry and those who pay for it. Verras creates high-performing hospitals, through a transformational process leveraging physician practices, clinical documentation, productivity, and organizational change management. It has been recognized and endorsed by the American Hospital Association.

Verras owns several proprietary and patented analytic solutions. These solutions include:

  • Acuity Index Method™ (AIM), a unique solution for severity adjustment of clinical data;
  • Verras Sherlock™, a one of a kind solutions for measuring clinical variation;
  • Verras Watson™, a solution developed to assemble each case at the order level and compare a single physician or group of physician’s cases to demonstrate best practice;
  • Medical Value Index™ (MVI), a patented method for calculating the value of hospitals compared both nationally and by markets.


Verras’ solutions and recent changes in the healthcare market have now uniquely positioned Verras to meet the new challenges. As a result of regulatory and reimbursement changes the Verras offerings are now perfectly aligned with industry needs. For the first time, hospitals are being reimbursed based on quality of care (value-based) rather than simply receiving “paid discount to charges”. Verras’ solutions are squarely focused on assisting all members of the healthcare continuum in enhancing value by improving quality of clinical care and reducing costs.

To learn more about Verras (Verras.com) and The Hospital Turnaround Company (hospitalturnaround.com), visit our websites or call Thomas Kish, President at 888-791-5556.

About ACHT

The American College of Healthcare Trustees (ACHT) is a national professional association dedicated to promoting high performing, competent, qualified, ethical governance and leadership in healthcare that is person-centered and accountable by providing continuing education, resources, and networking.

Become a Fellow of the American College of Healthcare Trustees now: https://bit.ly/joinACHT.

Share article on social media or email: